The Drug Enforcement Administration (DEA) in concert with the Department of Health and Human Services (HHS) issued a third extension of telemedicine flexibilities for the prescribing of controlled medications through December 31, 2025. Under this new regulation, providers can continue prescribing Schedule II-V controlled substances via telemedicine without having conducted …